Evidence map›Paper›PMID 37214407›Full record

ReviewFrontiers in neuroscience2023

A survey and perspective on neuromorphic continual learning systems.

Richa Mishra, Manan Suri

Abstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Richa Mishra *NVM and Neuromorphic Hardware Research Group, Department of Electrical Engineering, Indian Institute of Technology Delhi, New Delhi, India.
Manan Suri *NVM and Neuromorphic Hardware Research Group, Department of Electrical Engineering, Indian Institute of Technology Delhi, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the advent of low-power neuromorphic computing systems, new possibilities have emerged for deployment in various sectors, like healthcare and transport, that require intelligent autonomous applications. These applications require reliable low-power solutions for sequentially adapting to new relevant data without loss of learning. Neuromorphic systems are inherently inspired by biological neural networks that have the potential to offer an efficient solution toward the feat of continual learning. With increasing attention in this area, we present a first comprehensive review of state-of-the-art neuromorphic continual learning (NCL) paradigms. The significance of our study is multi-fold. We summarize the recent progress and propose a plausible roadmap for developing end-to-end NCL systems. We also attempt to identify the gap between research and the real-world deployment of NCL systems in multiple applications. We do so by assessing the recent contributions in neuromorphic continual learning at multiple levels-applications, algorithms, architectures, and hardware. We discuss the relevance of NCL systems and draw out application-specific requisites. We analyze the biological underpinnings that are used for acquiring high-level performance. At the hardware level, we assess the ability of the current neuromorphic platforms and emerging nano-device-based architectures to support these algorithms in the presence of several constraints. Further, we propose refinements to continual learning metrics for applying them to NCL systems. Finally, the review identifies gaps and possible solutions that are not yet focused upon for deploying application-specific NCL systems in real-life scenarios.

Indexed as

continual learningdigital architectureshardwareincremental learningin-memory computinglifelong learningneuromorphic algorithm

Identifiers

PMID37214407
PMCPMC10194827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.